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ABSTRACT
Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare autosomal dominant disease
caused by heterozygous mutations in the p63 gene and characterized by limb defects, orofacial
clefting, ectodermal dysplasia, and ocular defects. Patients develop progressive total bilateral
limbal stem cell deﬁciency, which eventually results in corneal blindness. Medical and surgical
treatments are ineffective and of limited beneﬁt. Oral mucosa epithelial stem cells (OMESCs)
represent an alternative source of stem cells capable of regenerating the corneal epithelium
and, combined with gene therapy, could provide an attractive therapeutic avenue. OMESCs
from EEC patients carrying the most severe p63 mutations (p.R279H and p.R304Q) were charac-
terized and the genetic defect of p.R279H silenced using allele-speciﬁc (AS) small interfering
RNAs (siRNAs). Systematic screening of locked nucleic acid (LNA)-siRNAs against R279H-p63
allele in (i) stable WT-DNp63a-RFP and R279H-DNp63a-EGFP cell lines, (ii) transient doubly
transfected cell lines, and (iii) p.R279H OMESCs, identiﬁed a number of potent siRNA inhibitors
for the mutant allele, which had no effect on wild-type p63. In addition, siRNA treatment led
to longer acquired life span of mutated stem cells compared to controls, less accelerated stem
cell differentiation in vitro, reduced proliferation properties, and effective ability in correcting
the epithelial hypoplasia, thus giving rise to full thickness stratiﬁed and differentiated epithelia.
This study demonstrates the phenotypic correction of mutant stem cells (OMESCs) in EEC syn-
drome by means of siRNA mediated AS silencing with restoration of function. The application
of siRNA, alone or in combination with cell-based therapies, offers a therapeutic strategy for
corneal blindness in EEC syndrome. STEM CELLS 2016; 00:000—000
SIGNIFICANCE STATEMENT
The Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare genetic disorder result-
ing from mutations in the p63 gene and characterized by ocular surface defects. Cell therapy
treatments based on transplantation of autologous corneal stem cells are not feasible for EEC
patients as both eyes are affected and corneal limbus severely compromised. Epithelial stem
cells deriving from the oral mucosa can be harvested with no limitations and grafts of oral
mucosa are normally used in ophthalmology to repair the ocular surface. However, being the
EEC syndrome a genetic disorder, cells will have to be genetically modified. Our genetic strat-
egy could provide a therapeutic window to correct the EEC defect and counteract the clinical
downstream effects of limbal stem cell deficiency.
INTRODUCTION
Ectrodactyly-Ectodermal dysplasia-Clefting (EEC)
syndrome (MIM#604292) is an autosomal-
dominant ectodermal dysplasia resulting from
mutations in the p63 gene and characterized by
limb defects, orofacial clefting, ectodermal dys-
plasia, and ocular defects. p63 is a transcription
factor essential for the regenerative prolifera-
tion of epithelial stem cells in the skin and
cornea. A healthy corneal epithelium is vital to
maintain the transparency and refractive state
of the cornea, which are essential for normal
vision and ocular comfort. The corneal epithe-
lium is a stratiﬁed epithelium from which super-
ﬁcial terminal cells are naturally shed, and the
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lost corneal epithelial cells are replaced by stem cells located at
the edges of the cornea, in a region known as the limbus. The
stem cells for the corneal epithelium are, therefore, more com-
monly known as limbal epithelial stem cells (LESCs) because of
their anatomical location. The p63 gene generates six isoforms
and DNp63a is the predominant isoform in the human corneal
epithelium [1]. DNp63a is necessary for the maintenance of the
proliferative potential of LESCs and essential for regenerative
proliferation in the ocular surface. The major cause of visual
morbidity in EEC syndrome is limbal stem cell deﬁciency (LSCD)
and we recently reported that the diminished ability of LESCs to
regenerate fully stratiﬁed corneal epithelia is related to p63
mutations [2, 3].
LSCD is characterized by conjunctival epithelial ingrowth,
neovascularization, recurrent corneal erosion, and persistent
ulcers, as well as corneal scarring [2, 4] and ultimately leads
to visual impairment and blindness. Transplantation of autolo-
gous LESC grafts has shown to be successful for the treatment
of acquired unilateral LSCD, but it is not feasible in cases of
bilateral LSCD, as in the EEC syndrome [5, 6]. Transplantation
of allogenic limbal epithelium is possible, but requires sys-
temic immunosuppression and it has a success rate that
decreases gradually over time (graft survival rate of 40% at 1
year and 33% at 2 years) [7]. For patients with bilateral LSCD,
transplantation of cultured autologous oral mucosal epithelial
cell sheets might be the only effective alternative for recon-
structing the ocular surface [8, 9]. Numerous studies have
shown that oral mucosal epithelial stem cells (OMESCs) are a
feasible alternative to limbal transplants [8–10], and an ideal
substitute of LESCs in ocular surface reconstruction [11].
Given that ﬁve p63 mutations account for almost 90% of
EEC cases and that the arginine (R) residues at position 304
(R304) and 279 (R279) are mutational hotspots, gene silencing
or editing strategies are required for a limited number of tar-
gets, making this approach an efﬁcient strategy applicable to
the majority of EEC patients. As EEC syndrome results from
heterozygous dominant-negative mutations in the p63 gene
therapeutic strategies based on allele-speciﬁc (AS) gene silenc-
ing through RNAi could speciﬁcally inhibit the expression of
disease-associated alleles without suppressing the expression
of the corresponding wild-type (WT) alleles to phenotypically
correct the stem cell population restoring function. Here, we
characterize OMESCs from patients with EEC syndrome and
demonstrate a proof-of-principle approach to correct the
underlying genetic defect by AS gene silencing. Phenotypic
correction of mutant p63 in OMESCs using small interfering
RNA (siRNA) mediated AS silencing restored full thickness
stratiﬁcation and differentiation of the epithelia. This study
supports the application of siRNA, alone or in combination
with cell based therapies as a therapeutic strategy for corneal
blindness in EEC syndrome.
MATERIALS AND METHODS
Cell Culture
Primary human keratinocytes were isolated from fresh oral muco-
sal biopsies of a healthy subject (aged 24) and two EEC patients
(both patients were 18 years old) after an informed consent form
was signed. The research program and the informed consent
forms were approved by the Venetian Ethical Committee for Clini-
cal Research Studies (Prot. 2009/77661, November 19, 2009).
Once isolated, cells were cultivated as previously described [12,
13]. The calculation method used for cell doublings and cumula-
tive population doublings was: 3,322*log10 (UCY/I), where
UCY5 the cell yield at that point and I5 number of clonogenic
cells. The clonogenic cells were calculated as the cell number
used as inoculum to begin that subculture multiplied by the
colony forming efﬁciency (CFE) value. Human embryonic kidney
cells stably transduced to express the simian virus 40 T antigen
(293T) were provided by D. Baltimore (Rockefeller University,
New York, NY).
Cell Proliferation Assay
The assay was performed in Silicone Culture-Insert in a 35-mm
dish that creates a 0.5-mm gap across the diameter of the well
(Ibidi, Madison,WI). Primary cells were cultured until conﬂuence,
then the insert was removed and the cell proliferation across the
gap monitored over time using A1Rsi1 Laser Scanning Confocal
Microscopy (Nikon Instruments Inc., Melville, NY).
[Ca
21
]i Measurements
[Ca21]i was measured by single-cell computer-assisted videoi-
maging using A1Rsi1 Laser Scanning Confocal Microscopy (Nikon
Instruments Inc., Melville, NY), as described before [14]. Brieﬂy,
3.53 105 OMESCs cells were plated one day prior to transfection
on glass coverslips, covered with UV-irradiated 3T3 cells, in 35-
mm dishes. Cells were loaded with 4lM Fluo-4/AM (Molecular
Probes, San Diego, CA; stock solutions of 1mM in dimethyl sulfox-
ide (DMSO), stored in aliquots at 220 8C). Transfected cells were
visualized using a 543-nm laser line (emission 570–600 nm) and
selected for analysis. Images were acquired every 4 s and stored
for ofﬂine analysis. Twenty to thirty-ﬁve individual cells were
selected and monitored simultaneously from each coverslip.
Fluo-4 ﬂuorescence intensity was expressed as an Fi/Fbasal-ratio,
where Fi is the background subtracted ﬂuorescence intensity and
Fbasal is the background subtracted mean ﬂuorescence value
measured from each cell at rest. All experiments were performed
at room temperature.
Hemicornea Preparation In Vitro
Human Keratoplasty Lenticules (HKLs) were prepared as previ-
ously described [15]. Brieﬂy, corneoscleral rims were preserved at
4 8C and used within 1–2 days from their excision. Each specimen
was ﬁrmly placed in an artiﬁcial chamber and the epithelium
manually removed after bathing the surface of the cornea with
an isotonic solution containing 5mg/ml of trypsin and 2mg/ml
of EDTA HKLs were obtained by microkeratome resection of
epithelium-free corneas. Epithelial stem cells were plated onto
HKLs at a concentration of 53 104 cells/cm2. Hemicorneas were
cultured under submerged conditions for 7 days and air-lifted for
14 further days.
Histology and Immunofluorescence
Hemicorneas were ﬁxed in 4% paraformaldehyde, embedded in
Optimal Cutting Temperature compound, frozen, and sectioned.
Sections (5–7lm) were analyzed using antibodies against DNp63a
(rabbit polyclonal, 1:200; PRIMM, Milan, Italy), keratin 3 (AE5
clone, mouse monoclonal, 1:100; MP Biomedicals, Solon, OH),
14-3-3r (rabbit polyclonal, 1:400; PRIMM), involucrin (goat polyclo-
nal, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA), laminin-b3
(goat polyclonal, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA)
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and Ki67 (mouse monoclonal, 1:100, Dako, Glostrup, DK) for 1 h at
37 8C. Fluoroscein-isothiocyanate (FITC) and rhodamine-conjugated
secondary antibodies (1:100; Santa Cruz Biotechnology, Santa Cruz,
CA) were used. Nuclei were stained with far-red ﬂuorescent DNA
dye (DRAQ5, 1:1000, Cell Signaling Technology, Boston, MA). For
ﬂuorescence quantiﬁcation experiments, monolayers of 63 104
cells were deposited on slides by means of Shandon CytoSpin 3
Cytocentrifuge. Specimens were analyzed with a Nikon CLSM.
Vectors
The human WT-DNp63a and R279H -DNp63a encoding regions
were obtained by reverse transcriptase-polymerase chain reac-
tion (RT-PCR) performed on total RNA from p.R279H-OMESCs,
employing speciﬁcally designed primers containing BamHI (PB1)
and PstI (R/C), respectively, at the 50 and 30 end and cloned into
the pCR2.1 TOPO-TA cloning plasmid. The red ﬂuorescent pro-
tein (RFP) encoding sequence was ampliﬁed from the pTAG-
RFP-T plasmid [16], while the EGFP fragment was derived from
pcDNA3.1eGFP by polymerase chain reaction (PCR). The
obtained PCR fragments, containing the PstI and the EcoRV
restriction sites at the 50 and 30 end, respectively, were cloned in
the pCR2.1 TOPO-TA cloning plasmid leading to TOPO-RFP and
TOPO-eGFP constructs, respectively. The internal ribosome
entry site (IRES)-Blasticidine cassette was ampliﬁed by PCR using
as a template the pWPI-blr employing primers IB50, containing
an EcoRV restriction site at the 50 end and IB30, containing an
XhoI restriction site at the 30 end [17]. The PCR fragment was
cloned in the pcR2.1 TOPO-TA cloning plasmid (TOPO-IRES-
BLAST). The ﬁnal pCDNA 3.1-based plasmids were constructed
by ligating into the backbone digested with BamH1-EcoRV, the
WT-DNp63a or R279H-DNp63a BamHI-PstI fragments, derived
from the pCR2.1-DNp63a or DNp63a R279H, respectively.
Expression is driven by the CMV promoter. The lentiviral vectors
were generated by digesting a pRRL.SIN-18.cPPT.CMV.GFP.WPRE
backbone with BamHI-Sal I and the following fragments
inserted: (i) WT-DNp63a or R279H-DNp63a as a BamHI-PstI frag-
ment derived from the pCR2.1-DNp63a or DNp63a-R279H,
respectively; (ii) RFP or EGFP cassette as a PstI-EcoRV fragment
derived from TOPO-RFP or TOPO-EGFP, and (iii) EcoRV-XhoI
fragment containing the IRES-Blasticidine obtained from the
TOPO-IRES-Blasticidine. All the plasmid-cloned fragments were
conﬁrmed by sequencing.
Production of Lentiviral Particles
Production of third generation HIV-derived vectors was achieved
by transient cotransfection of four plasmids into 293Tepithelial cell
line [18]. The HIV-derived packaging constructs were pMDLg/pRRE
and RSV-Rev, which contain: (i) the group-speciﬁc antigen (gag) and
pol genes under the control of a cytomegalovirus (CMV) promoter
and polyadengylation site of the human b-globin gene; (ii) the rev
cDNA. VSV G was expressed from pMD.G, meanwhile the transfer
constructs expressing the human WT DNp63a-RFP or R279H-
DNp63a-EGFP downstream CMV promoter were pRRL.SIN-18.
Forty-eight hours after transient transfection of the four plasmids
into HEK293T cells by Lipofectamine 2000 (Life Technologies, Carls-
bad, CA), supernatants were collected and then stored at280 8C.
Transduction with Recombinant HIV Particles
HEK293T cells were seeded onto 12-well tissue culture plates
at a density of 43 105 and transduced with recombinant viral
particles using a range of serial dilutions. After 3 days, DNAs
were analyzed by quantitative PCR, calculating the copy num-
ber of HIV sequences using primers and probes for GAG and
GADPH detection. Titers were around of 106–107 transducing
units/ml for each viruses.
Development of Stable Human DNp63a Cell-Lines
HEK293T cells (63 106) were seeded onto 10-cm tissue cul-
ture plates and transduced with recombinant viral particles
using a range of 0.5–1 multiplicity of infection (MOI). After 3
days, transduced cells were exposed to complete Dulbecco’s
modiﬁed Eagle’s medium supplemented with Blasticidin S HCl,
at a concentration of 10mg/ml. After about 2 weeks of selec-
tion, the arising clones were detached and subcloned into 24-
well plates for imaging selection. Clones showing a p63
nuclear staining comparable to that of primary keratinocytes
were expanded for further characterization.
Western Blot
Whole cell lysates for western blot were analyzed with the fol-
lowing primary antibodies: pan-p63 (4A4, mouse monoclonal,
1:500, Dako, Milan, Italy), p16ink4a (mouse monoclonal antibody,
1:500, Exalpha Biologicals, Shirley, MA), DNp63a (rabbit polyclo-
nal, 1:200; PRIMM, Milan, Italy), and GAPDH (rabbit polyclonal,
1:1000; Santa Cruz Biotechnology, Santa Cruz, CA). The band
intensities were quantiﬁed using an Image J analysis software.
The relative amount of p63 protein was normalized to glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH).
Senescence b-Galactosidase Cell Staining
b-Galactosidase activity was carried out in H-OMESCs, p.R279H-
OMESCs, and p.R304Q-OMESCs according to the manufacturer’s
instructions (Cell Signaling Technology, Danvers, MA).
Real-Time qPCR Assays
Total RNAs from primary keratinocytes and 293T cells were
extracted and puriﬁed using the RNeasy Micro kit (Qiagen,
Hilde, Germany). For the absolute DNp63a quantiﬁcation (Ab-
qPCR), the level of expression of the target gene was normalized
to (GAPDH). For the relative gene expression analysis (Rel-
qPCR), the difference in relative p63 expression was performed
using the 22DDCt method. GAPDH was used as internal control
gene. The percentage of WT or mutated mRNA DNp63a expres-
sion was measured by means of allele-speciﬁc real time (AS-
qPCR) assay [3]. Primers and probes are shown in Table 1.
siRNA Sequence Walk and Transfection
All possible siRNAs (n5 19) were designed to target the R279H-
p63 mRNA region containing a single-nucleotide change (G-A at
nucleotide position 953 resulting in the amino acid change,
R279H). They: (i) have a sequence of 19 nucleotides; (ii) incorpo-
rate the locked nucleic acid (LNA); (iii) were obtained as single
stranded from Exiqon (Exiqon, Vedbaek, Denmark) and prepared
as reported [19]. All siRNAs were transfected into (i) 293T cells
stably expressing either the human DNp63a or DNp63a-R279H,
(ii) serially propagated primary keratinocytes, and (iii) organo-
typic cultures with Lipofectamine 2000 (Life Technologies,
Carlsbad, CA).
Dose Titration Analysis
Titration of siRNA a was performed using a narrow range of siRNAs
from 0.1 to 10nM in 293T HEK DNp63a stable cell lines and from
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0 to 100nM in OMESCs. Residual WT- and R279H-DNp63a protein
levels was measured by means of laser scanning confocal micros-
copy, while transcript levels of WT and mutated R279H mRNAs
were quantiﬁed by means of AS-qPCR. Concentration-response
curves were obtained by ﬁtting the data to the four parameter
logistic equation y5min1 (max 2 min)/(11 (x/IC50)n), where y
is the normalized value of real-time PCR or imaging values, x is the
siRNA concentration in nanomoles per liter, and n is the Hill coefﬁ-
cient. Data ﬁtting was obtained with the Origin software (OriginLab
Ltd., Northampton, MA).
Statistical Analysis
All data are reported as mean6 S.E.M. When comparing two
data sets, the Student’s t test for unpaired data was used. To
compare multiple groups, statistical comparisons were per-
formed with one-way or two-ways ANOVA followed by Tukey-
Kramer post hoc test. Signiﬁcance is at p< .05. Statistical
comparisons were carried out using the Graph-PAD 3.02 soft-
ware suite (GraphPad Software Inc., San Diego, CA).
RESULTS
p63-Defective Oral Epithelial Cells Undergo a Rapid
Exhaustion of Clonogenic and Self-Renewal Potential,
Resulting in Accelerated Ageing
To investigate how p.R279H and p.R304Q p63 mutations affect
LESC physiology in EEC syndrome, OMESCs from healthy
(H-OMESCs, n5 1) or EEC individuals (EEC-OMESCs, n5 2, with
heterozygous p.R279H and p.R304Q p63 mutations) were iso-
lated from oral mucosal biopsies and serially propagated until
exhaustion. Compared to H-OMESCs, EEC-OMESCs showed (i) a
more rapid decrease of CFE and clonogenic cell numbers (Fig.
1A, 1B), (ii) progressive increased percentage of aborted colo-
nies during serial cultivation (Fig. 1C), and (iii) increased replica-
tive senescence, as suggested by the lower number of cell
passages in culture (Fig. 1D). As previously reported in papers
describing the effects of the loss of p63 [20, 21], cell growth was
faster in EEC-OMESCs, with cultures becoming conﬂuent in 4–5
days compared to 6–7 days observed in H-OMESCs controls. In
addition, we also observed that EEC-OMESCs proliferate at a
faster rate compared to controls, both at 4 h or 7 h after the
insert was removed (Fig. 1E). Percentage of wound closure
was also increased in EEC-OMESCs compared with H-OMESCs;
speciﬁcally H-OMESCs showed 1.06 0.2% and 326 4% closure
at 4 h and 7 h, respectively, whereas p.R279H OMESCs showed
66 1% and 586 3% closure at 4 h and 7 h, respectively and
p.R304Q OMESCs 156 1% and 866 7% closure at 4 h and 7 h,
respectively (Fig. 1F). To demonstrate that p63 mutant cells
undergo accelerated ageing, we performed a senescence-
associated-beta galactosidase staining (Fig. 1G) and western
blot of p16 and DNp63a at different cell passages (1 and 7)
(Fig. 1H) in H-OMESCs, p.R279H-OMESCs, and p.R304Q-
OMESCs.
Mutations in p63 Lead to Abnormal Stratification
of Epithelia and Differentiation Pathways
We evaluated the ability of p63-defective EEC-OMESCs to
stratify and differentiate in a HKL model [15]. Primary healthy,
p.R279H, and p.R304Q OMESCs at passage two were seeded
onto HKLs and grown for 21 days. Compared to H-OMESCs
controls, epithelia generated by EEC-OMESCs were hypoplastic
with defects in epithelial thickness and cellularity with some
areas devoid of cells and with ﬂat irregular and terminally dif-
ferentiated cells (Fig. 2A). Quantitatively, epithelial thickness
was reduced when p.R279H OMESCs (mean: 12.16 7 lm;
maximum: 21.3lm) or p.R304Q OMESCs (mean: 9.16 3.0 lm;
maximum: 14.5lm) were compared to epithelia obtained
from H-OMESCs (mean: 56.46 18.0lm; maximum: 82.3lm).
The number of cell layers in the epithelium was higher in
HKLs seeded with H-OMESCs (mean: 3.96 1.2 cell layers;
maximum: 5.8 cell layers), compared to those with p.R279H
OMESCs (mean: 1.26 1.3 cell layers; maximum: 2.2 cell
layers) and with p.R304Q OMESCs (mean: 1.16 1.0 cell layers;
maximum: 1.2 cell layers). Ultrastructural analyses with laser
scanning confocal microscopy showed that epithelia from
H-OMESCs were organized into (i) basal column-shaped cells
expressing p63, (ii) ﬂat squamous superﬁcial terminally
Table 1. List of primers and probes used in Ab-qPCR and AS-qPCR
PB1 50-CGCGGATCCGCTAACATGTTGTACCTGGAAAACAATGC-30
R/C 50-CCAATGCATTGGTTCTGCAGTCCCTCCCCCTCCTC-30
50RFP 50-AAAACTGCAGGTGGTGTCTTAAGGGCGAAGAG-30
30RFP 50-AAAACTGCAGGTGGTGTCTAAGGGCGAAGAG-30
50GFP/G 50-AAAACTGCAGGTGGTGAGCAAGGGCGAG-30
30GFP 50-GATATCTTACTTGTACAGCTCGTCC-30
IB5’ 50-GATATCCGCCCCCCCCCCCCTAACGTTAC-30
IB30 50-CCGCTCGAGTTAGCCCTCCCACACATAACC-30
GAG Fw 50-GGAGCTAGAACGATTCGCAGTTA-30
GAG Rev 50-GGTTGTAGCTGTCCCAGTATTTGTC-30
GAG Probe 50-[6FAM]ACAGCCTCCTGATGTTTCTAACAGGCCAGG[BHQ1]-30
GADPH Fw 50-CCACTCCTCCACCTTTGACG-30
GADPH Rev 50-CATGAGGTCCACCACCCTGT-30
GADPH Probe 50-[TET]TTGCCCTCAACGACCACTTT[TAM]-30
DNp63a Fw 50-GCATTGTCAGTTTCTTAGCGAG-30
DNp63aRev 50-CCATGGAGTAATGCTCAATCTG-30
DNp63a Probe 50-[6FAM]GGACTATTTCACGACCCAGG[BHQ1]-30
WT-DNp63a 50-[6FAM]AATTGGACGGCGGTTCATCC[BHQ1]-30
R279H-ANp63a 50-[TET]AATTGGACGGTGGTTCATCCC[BHQ1]-30
Abbreviations: Ab-qPCR, absolute quantitative PCR; ASqPCR, allele-speciﬁc quantitative PCR; GAG, group-speciﬁc antigen; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; GFP, Green Fluorescence Protein; RFP, red ﬂuorescent protein.
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differentiated cells, as indicated by the expression of keratin 3
and involucrin, (iii) suprabasal cuboid wing cells, expressing
14-3-3r, an early differentiation marker for stratiﬁed epithelia,
and (iv) proliferating cells, expressing Ki67 (Fig. 2B). The basal
cuboidal cell layer was ﬁrmly attached to the underlying
extracellular matrix and to the basement membrane (Fig. 2B,
top panel). In contrast, tissues generated from EEC-OMESCs
showed defects in both stratiﬁcation and differentiation, thus
resulting in severe tissue hypoplasia and lack of proper tissue
polarity (Fig. 2B, middle and bottom panels), but not in
Figure 1. p.R279H and p.R304Q OMESCs show altered clonogenic ability and proliferative potential. Life-span analysis of OMESCs from
healthy (H-) or p.R279H and p.R304Q ectrodactyly-ectodermal dysplasia-clefting (EEC) donors. Data have been obtained from three unre-
lated normal subjects and from biopsies of two unrelated EEC patients. (A): Colony forming efﬁciency of healthy, p.R279H and p.R304Q
OMESCs was evaluated at the cell passages indicated. Images are representative of data obtained from at least four independent experi-
ments. Quantiﬁcation of (B) clonogenic cells numbers, (C) percentage of aborted colonies, (D) cell doublings and cumulative population
doublings of healthy (black line), p.R279H (gray line), and p.R304Q (blue line) OMESCs are shown. EEC-OMESCs were passaged 5–6
times (5 35–36 days) compared to the 11 passages, that is, 73 days in culture, seen in H-OMESCs controls. All data are expressed as
mean6 SEM (n5 3 independent experiments). (E): Cell proliferation assay of OMESCs from healthy or p.R279H and p.R304Q EEC
donors. Images captured at 4 and 7 h after the silicon insert removing (n5 3 independent experiments). (F): Quantiﬁcation of the cell
proliferation assay. Results are expressed as percentage of closure over the wound area (n5 3 independent experiments). (G): Beta-
galactosidase staining performed on H-OMESCs, p.R279H-OMESCs, and p.R304Q-OMESCs (scale bars5 200 lm). (H): Western blot of
DNp63a and p16 in H-OMESCs, p.R279H-OMESCs, and p.R304Q-OMESCs at different cell passages (1 and 7). Abbreviations: GAPDH, glyc-
eraldehyde 3-phosphate dehydrogenase; OMESCs, oral mucosa epithelial stem cells; SEM, standard error of the mean.
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proliferation (Ki67 is similar in EEC and healthy cells). We also
observed anomalous clusters of terminally differentiated cells
strongly expressing keratin 3 and involucrin (terminal differen-
tiation marker for stratiﬁed epithelia), but not p63 and low
14-3-3r, indicative of a premature terminal differentiation
phenotype (Fig. 2C). As previously reported [22], we also
observed reduced adhesion properties of the epithelium
obtained by mutant cells (Fig. 2B, 2C).
Cells are known to progressively lose sensitivity to extrac-
ellular calcium as they proceed further along the differentia-
tion process [23–30]. Since EEC-OMESCs display defective
differentiation and stratiﬁcation, we speculated that cellular
calcium cycling is altered in cells expressing p63 mutants. Spe-
ciﬁcally, we analyzed capacitative calcium entry, one of the
main calcium inﬂux pathway of not-excitable cells, in
H-OMESCs and EEC-OMESCs (at the third passage, when dif-
ferentiation has already developed). When intracellular cal-
cium store was depleted to activate capacitative channels
[31], we found that, compared to H-OMESCs controls, the
capacitative calcium entry was signiﬁcantly reduced both in
p.R279H and p.R304Q OMESCs, as a likely consequence of the
premature accelerated differentiation of the mutated cells
(Supporting Information Fig. 1).
DNp63a Expression in Cells from Healthy
and p.R279H EEC Donors
Given that p63 accumulation, due to higher stability of the
EEC mutated isoform, has been previously observed in tissues
Figure 2. p.R279H and p.R304Q p63 mutations lead to abnormal epithelial stratiﬁcation and differentiation pathways. (A):
Hematoxylin-eosin staining of epithelia generated on human keratoplasty lenticules by healthy, p.R279H and p.R304Q primary OMESCs
at passage 2 (n5 3, scale bars5 50 lm). (B): Double-immunoﬂuorescence on epithelia derived from the above OMESCs using p63(red)/
K3(green), 14-3-3r (red, Ki67 (green), and involucrin (orange) antibodies (n5 3, scale bars5 20 lm). (C): Immunoﬂuorescence performed
on the anomalous clusters of terminally differentiated p.R279H OMESCs using p63 (red), K3 (green), involucrin (orange), and 14-3-3r
(red) antibodies (n5 3, scale bars5 50lm). Abbreviations: OMESCs, oral mucosa epithelial stem cells; K3, keratin 3.
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of patients affected by EEC syndrome [32], DNp63a expres-
sion in p.R279H OMESCs was quantiﬁed using an absolute
quantitative PCR at different passages in culture (I, III, V, VII,
and XI) and compared to H-OMESCs and healthy-limbal epi-
thelial stem cells (H-LESCs). As shown in Figure 3, DNp63a
decreased during serial cultivation, becoming very low after the
seventh passage. The rate of reduction was faster in p.R279H
OMESCs, compared to H-OMESCs and H-LESCs. DNp63a expres-
sion was threefold higher in p.R279H OMESCs compared to H-
OMESCs, at the ﬁrst passage. This correlates well with the
abnormal hyperproliferation of p.R279H EEC primary cells, pre-
viously observed in the CFE and cell proliferation assays (Fig. 1A,
1E). This most likely results from an impaired negative regula-
tory loop, which is DNp63a-dependent, needed for cell-cycle
arrest, and for the initiation of a differentiation program [33].
Importantly, the amount of DNp63a in primary H-LESCs was
approximately two times lower than in H-OMESCs. This corre-
lates well with their “cumulative population doubling ability”
observed in vitro (H-LESCs5 106 2 passages; H-OMESCs5
126 2 passages) [34] and reﬂects the different “intrinsic life-
span” and “clonogenic potential” of the two cell lineages. Our
ﬁndings conﬁrm that DNp63a is a robust stem cell marker: (i) its
expression declines during the differentiation and senescence
processes of primary epithelia stem cells in vitro and (ii) also
provide further evidences of the premature differentiation
found in EEC-OMESCs. To gain greater insight into the relation-
ship between DNp63a expression and EEC pathogenesis, we
evaluated the percentage of WT or mutated mRNA p63 expres-
sion through allele-speciﬁc quantitative PCR (AS-qPCR). AS-
qPCR demonstrated that the proﬁle expression ratios of two
transcripts were different in three passages analyzed (I, III, and
V) with a decrease of the mutated p63 mRNA (Fig.3, green and
red indicate mutant and WT expression levels, respectively). At
the ﬁrst passage, the percentages of mutant R279H p63 mRNA
and WT p63 mRNA were 606 7% and 406 5% respectively,
while during the differentiation process, these ratios decreased
to 126 1.7% and 236 0.9%, respectively.
Establishment of a p.R279H EEC Model System
To screen the efﬁciency of siRNAs to block the expression of
mutant p63 with little or no effect on WT p63, we established
two cellular models stably expressing WT-DNp63a or R279H-
DNp63a HEK293T cells, an epithelial cell line with no endoge-
nous p63 expression, were transduced with third generation
lentiviruses carrying WT- or R279H-DNp63a alleles fused to RFP
or EGFP sequences, respectively (Fig. 4A). After the isolation of
stable clones (n5 14 for both constructs), we observed that all
the cell lines carrying the R279H-DNp63a allele showed higher
levels of DNp63a expression, at the mRNA expression level,
than control clones expressing WT-DNp63a (Supporting Infor-
mation Fig. 2A). Considering that (i) both WT than R279H-
DNp63a cell lines were obtained using the same transduction
and selection conditions and (ii) the same results were also
obtained after transient transfection, the hypothesis is that our
cell model mirrors the higher amount of R279H-DNp63a, previ-
ously found and described ex vivo in p.R279H OMESCs. To test
our hypothesis and screen the ability of siRNAs to counteract
the R279H-p63 expression, we chose two clones (WT#9 and
R279H#2) that exhibited the typical nuclear localization signal of
DNp63a and expressed, in toto, mRNA and protein levels of
DNp63a comparable to the endogenous level found in EEC-
OMESCs (Supporting Information Fig. 2A, 2B).
Systematic Screening of LNA-siRNAs Against
the R279H-p63 Allele
Stable cell lines were used to separately transfect a collection of
19 LNA siRNAs [35, 36], designed to target the R279H-p63
mRNA region containing the single nucleotide change. Forty-
eight hours post siRNA transfection, AS downregulation was
assessed through DNp63a relative-qPCR. siRNAs (a, b, and c)
speciﬁcally downregulated the R279H-DNp63a mRNA by
approximately 90% (Fig. 4B). Interestingly, some siRNAs upregu-
lated R279H-DNp63a (r and s), suggesting an interference with
the DNp63a post-transcriptional regulation pathway. No
changes in cell viability were observed after siRNA transfection.
Western-blot analyses demonstrated a signiﬁcant and speciﬁc
reduction of mutant DNp63a protein when siRNA a was used
(456 4%), while protein downregulation with siRNA b and
siRNA c did not have consistent and reproducible effects (Fig.
4C, 4D). Imaging analyses of the two HEK293T-DNp63a stable
lines treated with doses of siRNA a ranging from 0 to 10 nM (0,
0.1, 1, and 10 nM) showed that compared to a nontargeting
control siRNA (siNCT; negative control), siRNA a (i) reduced the
expression of R279H-DNp63a-EGFP protein in a concentration-
dependent way, reaching 436 5% at 10 nM, (ii) maintained the
ﬂuorescence of the WT-DNp63a-RFP protein, and (iii) had an
IC50 of 3.156 0.79 nM, showing a potent inhibitory effect
in vitro (Supporting Information Fig. 2C-2E).
To evaluate the speciﬁcity of siRNA a to (1) inhibit the
R279H-DNp63a neo-synthesis, and (2) downregulate its expres-
sion in time-dependent manner, we utilized transiently trans-
fected HEK293T cell lines, as an in vitro cellular model of the EEC
disease-related heterozygous state. The HEK293T cell line was
cotransfected with a 1:1 ratio of both WT-DNp63a-RFP and
mutant DNp63a-EGFP plasmids in the presence of the siRNA a.
We observed a speciﬁc and signiﬁcant neo-synthesis inhibition
of R279H-DNp63a-EGFP expression in approximately 80% of
total cells at 48 h post transfection when compared to siNCT-
Figure 3. DNp63a expression in cells from healthy and p.R279H
ectrodactyly-ectodermal dysplasia-clefting donors. Absolute quantita-
tive PCR showing DNp63a copy number in total RNA from LESCs, H-,
and p.R279H OMESCs, and allele-speciﬁc quantitative PCR (AS-qPCR) of
R279H-p63 mutant during the passages. For the Ab-qPCR, results were
normalized against GADPH. AS-qPCR data indicate the percentage of
R279H-p63 allele compared to WT-p63. Data represent mean6 SEM.
Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
LESC, limbal epithelial stem cell; OMESCs, oral mucosa epithelial stem
cells.
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Figure 4. siRNA a speciﬁcally inhibits R279H-DNp63a expression in a time-dependent manner in DNp63a expressing cell lines. (A): Third
generation HIV-derived vectors include a modiﬁed 50 and 30 LTR, a packaging signal (w), RRE, and central polypurine tract (PPT). WT- or
R279H DNp63a-cDNAs have stop codons fused to RFP or Green Fluorescence Protein (GFP), respectively, followed by IRES and blasticidin
resistant gene. (B): Relative-qPCR showing DNp63a mRNA downregulation in RNAs extracted from WT-DNp63a and R279H-DNp63a
HEK293T stable cell lines either untreated (U) or transfected with control (S) or DNp63a siRNAs at 10 nM. (C): Immunoblot detection of
DNp63a in WT- and R279H-DNp63a HEK293T cells transfected with control (siNCT) or selected DNp63a siRNAs (n5 5). (D): Western blot
quantiﬁcation shows DNp63a levels in the WT-DNp63a and R279H-DNp63a HEK293T cells. Data are expressed as mean6 SEM (n5 5).
**p< .01. (E): Scanning confocal microscope analyses of HEK293 cells transiently transfected with WT-DNp63a-RFP and R279H-DNp63a-
EGFP plasmids, in combination with siNCT or siRNAa, 48 h post-transfection. TL indicates transmitted light, red indicates RFP-fused WT-
DNp63a protein, green indicates EGFP-fused R279H-DNp63a isoform and yellow indicates colocalization of both isoforms (magniﬁca-
tion5310; scale bars5 100 mm). (F): Time-point ﬂuorescence quantiﬁcation of WT-DNp63a-RFP and R279H-DNp63a-EGFP transiently
expressed in HEK293T cells, cotransfected with siNCT. Data are expressed as mean6 SEM (n5 4 independent experiments). (G): Time-point
quantiﬁcation of protein ﬂuorescence of WT-DNp63a-RFP and R279H-DNp63a-EGFP transiently expressed in HEK293T cells, cotransfected
with siRNA a. Data are expressed as mean6 SEM (n5 4 independent experiments). (H): Z-stack (3D) and orthogonal ﬂuorescent images of
HEK293T cells transiently transfected with WT-DNp63a-RFP and R279H-DNp63a-EGFP plasmids, and treated with a combination of ﬂuores-
cein isothiocyanate (FITC)-siRNA and siRNA a, 18 h post-transfection (time-points indicate hours from the WT-DNp63a-RFP and R279H-
DNp63a-EGFP plasmids transfection; magniﬁcation53300; scale bars5 10 mm). Red indicates RFP-fused WT-DNp63a protein, green indi-
cates EGFP-fused R279H-DNp63a isoform and FITC-siRNA and blue indicates nuclei of cells stained with DRAQ5. Abbreviations: EGFP,
enhanced green ﬂuorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LTR, long terminal repeat; RFP, red ﬂuorescent
protein; RRE, rev response element; siRNA, small interfering RNA; WT,Wild type.
treated cells (Fig. 4E-4G). In further experiments, siRNA a was
subsequently added to transiently cotransfected cells, together
with ﬂuorescein labeled siRNA (FITC-siRNA) to follow the deliv-
ery of the siRNAs. Z-stack imaging and orthogonal analyses of
the ﬂuorescent cells showed a speciﬁc time-dependent silencing
of R279H-DNp63a-EGFP. Forty-eight hours post transfection a
maximum effect was observed in siRNA a1 FITC-siRNA targeted
cells (Fig. 4H). We further wanted to validate the inhibitory
potential of our most discriminating and potent AS siRNAs ex
vivo. To estimate the transfection efﬁciency of siRNAs in human
OMESCs and to allow direct observation of their cellular uptake,
distribution, and localization, primary p.R279H OMESCs were
transfected using concentrations of FITC-siRNA ranging from 10
to 100 nM (10, 25, 50, 75, and 100 nM). Forty-eight hours post
transfection, the optimal transfection efﬁciency was of 886 2%
at 100 nM (Fig. 5A). Subsequently, we serially transfected the
siRNA c, siRNA a, and siRNA b in the primary p.R279H OMESCs
at 100 nM, and the expression levels of WT and R279H-p63
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were measured using AS-qPCR. Ampliﬁcation plots of WT (blue
curves) and mutated mRNA (green curves) output from (i) siNCT,
(ii) siRNA c, (iii) siRNA b, (iv) siRNA a, and (v) the H-OMESCs
samples are shown in Figure 5B. Signiﬁcant suppression of
mutant mRNA occurred with siRNA a, and also with siRNA b and
c, which suppressed mutant mRNA levels up to 80%, 72%, and
65% with respect to untreated cells, respectively. To determine
the minimum concentration of siRNA a needed to knockdown
the R279H-p63 mRNA, a dose-response (concentration) analysis
was performed within a narrow range of 0, 1, 10, and 100 nM
and the transcript levels evaluated with AS-qPCR. As shown in
Figure 5C, titration of siRNA a abolished the R279H mRNA,
showing a gradient of values which correlated with the concen-
tration used, with an IC50 of 7.206 0.04 nM (Fig. 5D). siRNA a
was, therefore, able to downregulate the mutated allele without
altering the expression of the WT-DNp63a both in vitro and
ex vivo.
Restoration of Premature Clonogenic and Proliferative
Arrest in R279H-p63 Primary Cells by Long-Term siRNA
a Treatment
To investigate whether siRNA a could restore the functional
phenotype in p.R279H OMESCs, we repeated the cell prolifer-
ation assays with OMESCs treated with either siNCT or siRNA
a (at 100 nM). Imaging analyses revealed that the wound clo-
sure at 4 and 7 h was reduced in p.R279H OMESCs treated
with siRNA a, but not with siNCT, and the closure kinetics
were more similar to control H-OMESCs (Fig. 5E, 5F). Further-
more, p.R279H OMESCs treated with siRNA a (but not with
siNCT) had a longer life-span and were able to be passaged in
culture seven times compared to 5–6 with H-OMESCs. Finally,
siRNA a treatment speciﬁcally mitigated the progressive loss
of clonogenic cells in p.R279H OMESCs, and a trend more
similar to H-OMESCs was achieved (Fig. 5G), as also conﬁrmed
by the results of the CFE assay (Fig. 5H). At the concentration
of siRNA used, no signiﬁcant alterations were observed in
both the keratinocyte morphology and the expression level of
markers such as p63, DNp63a, MUC1, K3, K4, and K13 in
siRNA a-treated OMESCs.
Impaired Epithelial p.R279H OMESCs Stratification and
Differentiation is Rescued by siRNA a Infusion
To test the ability of siRNA a to restore the epithelial tissue phe-
notype, two simultaneous organotypic cultures of p.R279H
OMESCs were established using a device able to create two dif-
ferent and separated areas in a single HKL (Fig. 5I). One area
was treated with siRNA a and the adjacent with a scrambled
siRNA (siNCT) (Fig. 5J). FITC-siRNAs were also added to track dis-
tribution. At the end of the culture, histological sections of the
tissues were taken to assess the ability of p.R279H OMESCs to
correctly stratify following siRNA a treatment (Fig. 5K) and com-
pared to control (Fig. 5L). Confocal microscopy demonstrated
the presence of a well-organized and stratiﬁed epithelium of 4–
5 layers limited to the area treated with siRNA a, while the adja-
cent region showed the typical phenotype of the p63-mutated
cells. The resulting epithelium was characterized by basal
expression of p63 and DNp63a while expression of keratin 3 and
14-3-3r was mainly found in the upper cell layers. The basal
cuboidal epithelial cells were anchored to the basement mem-
brane and expressed b3-laminin.
DISCUSSION
AS gene silencing has previously been described for the treat-
ment of Amyotrophic Lateral Sclerosis [37, 38] and other genetic
diseases [39, 40]. For the cornea, AS siRNAs have been success-
fully developed against the mutant allele of the KRT12 gene for
a severe form of Meesmann Epithelial Corneal Dystrophy [41].
AS siRNAs represent a potential approach to treat the heterozy-
gous dominant-negative p63 mutations which result in EEC syn-
drome and corneal blindness due to LSCD.
In this study, we characterized OMESCs from patients with
EEC syndrome and demonstrated a proof-of-principle approach
Figure 5. siRNA a restores the epithelial phenotype, stratiﬁcation and differentiation properties of p.R279H OMESCs. (A): Scanning con-
focal microscope images of p.R279H OMESCs transfected using ﬂuoroscein-isothiocyanate (FITC)-siRNAs ranging from 10 to 100 nM (10,
25, 50, 75, and 100 nM). Forty-eight hours post-transfection, the optimal transfection efﬁciency was of 886 2% at 100 nM. Yellow indi-
cates FITC-fused scramble siRNA (magniﬁcation:3 10; scale bars: 50 mm). (B): Four representative allele-speciﬁc quantitative PCR (AS-
qPCR) plots of WT- and R279H-p63 mRNA expression in p.R279H OMESCs transfected with 100 nM of siNCT or siRNA c, siRNA a, or
siRNA b. Both Ct and end-point values of the R279H-DNp63a mRNA are correlated with the mutated allele silencing, reaching respec-
tively the 72%, 80%, and 65%. Violet indicates WT- and green indicates R279H-p63 mRNAs. (C): A representative AS-qPCR plot of WT-
p63 and R279H-p63 expression in p.R279H OMESCs transfected with a range of 0, 1, 10, and 100 nM of siRNA a, 48 h post-transfection.
Image is representative of data obtained from at least three independent experiments. Violet indicates WT-p63 mRNA and green indi-
cates R279H mRNA. (D): Concentration-response curves of WT- and R279H-DNp63a mRNAs values in OMESCs, obtained from at least
three independent AS-qPCR experiments. The value of the Hill coefﬁcient was 1.546 0.7. (E): Laser scanning confocal microscope images
of the wound healing assay, performed on healthy (H-OMESCs) and ectrodactyly-ectodermal dysplasia-clefting donors cells (p.R279H-
OMESCs), with control (siNCT) or siRNA a treatment, at the indicated time after the silicone insert was removed. Images are representa-
tive of at least two independent experiments. (F): Quantiﬁcation of the wound closure assay. Data indicate the percentage of the wound
closure relative to the total area of the scratch. All data are expressed as mean6 SEM and derived from at least two independent
experiments. *p< .05, ***p< .001. (G): Colony forming efﬁciency (CFE) assay of WT-p63 and p.R279H OMESCs, continuously exposed to
siNCT or siRNA a, evaluated at the cell passages indicated. siRNA a effectively reestablishes the clonogenic ability and proliferation prop-
erty of the p63 mutant cells. All data are expressed as mean6 SEM and derived from at least three independent experiments. *p< .05,
**p< .01. (H): CFE assay at passages I to IV after treatment of p.R279H OMESCs cells with siRNA a. (I): Photos of the device used to
create two different areas in human keratoplasty lenticules. Red line indicates the area treated with siRNA a, the yellow line indicates
the area treated with a control siRNA (siNCT), both in combination with a yellow ﬂuorescent placebo siRNA (F-siRNA). (J): Hystological
images of organotypic cultures made with p.R279H OMESCs, treated for at least 2 weeks with siRNA a or siNCT, in combination with
the ﬂuorescent siRNA. The continuous infusion of siRNA a induces the proper stratiﬁcation and differentiation of p.R279H cells. Images
of cells containing the yellow ﬂuorescent molecule indicate that cells actively divided after siRNA a treatment; scale bars: 100 lm. Mag-
niﬁcation of immunoﬂuorescence images from organotypic cultures treated with siRNA a (K) or with a scrambled siRNA (L) obtained
with pan-p63, DNp63a; b3-laminin, and 14-3-3r show the appropriate expression of these proteins. Images are representative of data
obtained from at least three independent experiments. Scale bars5 20lm. Abbreviations: F-siRNA, FITC-small interfering RNA; OMESCs,
oral mucosa epithelial stem cells; siRNA, small interfering RNA; WT, wild type.
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Figure 6. Model of siRNA-based therapeutic approach for LSCD treatment in ectrodactyly-ectodermal dysplasia-clefting (EEC) patients.
p63-defective-LESCs have a reduced ability to repopulate the corneal epithelium, which leads to progressive visual impairment culminat-
ing in complete bilateral blindness, associated with conjunctivalization. Gene silencing approaches by means of allele-speciﬁc siRNAs is
potentially a new way to revert the epithelial defects and, eventually, severe visual loss observed in young and adult EEC patients. In
young EEC patients, who still have LESCs in the limbus, eye drops containing mutant-speciﬁc siRNAs could counterbalance the loss of
stem cells. In adult EEC patients, who have a more severe LSCD and no limbus left, gene correction mediated by continuous supplying
of speciﬁc siRNAs can improve the clinical outcomes of autologous OMESCs graft. Abbreviations: LESCs, limbal epithelial stem cells;
LSCD: limbal stem cell deﬁciency; OMESCs, oral mucosa epithelial stem cells; siRNA, small interfering RNA.
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to correct the underlying genetic defect in p63 using AS gene
silencing. Since transplantation of OMESCs has previously shown
to be a valid alternative for reconstructing the ocular surface in
bilateral LSCD patients, we initially characterized OMESCs isolated
from two EEC patients carrying the most severe mutations affect-
ing the cornea: p.R279H and p.R304Q. Compared to controls,
both mutants showed (i) premature clonogenic and proliferative
stop; (ii) increased replicative senescence; (iii) altered wound
healing properties; (iv) reduction of the capacitative calcium
entry and (v) defects in stratiﬁcation and differentiation, thus
resulting in severe epithelial hypoplasia and lack of proper tissue
polarity. These characteristics explain some of the clinical features
of the ocular surface seen in EEC patients: progressive conjunctiv-
alization of the cornea, recurrent corneal erosions, and ulcers
that get worse along with the years.
Characterization of OMESCs and AS gene silencing experi-
ments allowed us to make two important ﬁndings. First, OMESCs
display a higher self-renewal potential than LESCs, thus support-
ing further their use as an alternative source of cells for the treat-
ment of LSCD. Second, consistent with the ﬁnding that mutant
R279H p63 mRNA is more stable than WT [32], we found that
DNp63a accumulates in OMESCs carrying the p.R279H mutation
and its expression declines during the differentiation and senes-
cence processes of primary cells in vitro faster than in WT cells.
Considering the role of DNp63a in LESCs [1–6], this mis-
regulation may have the functional consequence to induce a pre-
mature stop to cell proliferation and to allow the alteration of the
differentiation pathway. The accumulation of DNp63a in p.R279H
OMESCs is, at least in part, due to the increased stability of the
transcriptionally inactive R279H mutant [32], that negatively
interferes with the p63 autoregulatory loop active in stem cells
[42]. The speciﬁc silencing of the mutated allele may, therefore,
have several advantages and reduce both the amount of tran-
scriptionally inactive p63 and the inhibition of the transactivation
of the WT p63, mediated by the R279H protein, which is neces-
sary for the activation of the autoregulation loop. All our experi-
ments pointed toward the efﬁcacy and efﬁciency of siRNA a, as
the R279H-DNp63a-mutant protein was speciﬁcally knocked
down by approximately 80% while the WT was stably expressed
and unaffected. In addition, siRNA a-treated p.R279H OMESCs
showed longer life-spans, reduced proliferation properties, and
effective ability in correcting the epithelial hypoplasia, thus giving
rise to a full thickness stratiﬁed and differentiated epithelia.
Depending on the timing and severity of LSCD, our results
might have clinical applications both for young and adult EEC
patients. EEC-related corneal pathology follows a clear clinical
course with LSCD usually manifesting in the second to third dec-
ade leading to severe corneal failure in the fourth to ﬁfth dec-
ade [2]. This provides a therapeutic window to correct the
genetic defect using genetic preventive strategies, which could
maintain corneal clarity, prevent blindness, and obviate pain
and photophobia. In early corneal disease, with LESCs still pres-
ent in the limbus, the use of eye drops containing mutant-
speciﬁc siRNAs may be a practical therapeutic option. In
patients with established LSCD and no limbal stem cell popula-
tion, clinical outcomes may be improved by ex vivo gene correc-
tion of OMESCs with p63 mutant-speciﬁc siRNAs (Fig. 6).
CONCLUSIONS
In summary, we truly believe that our strategy could provide
a therapeutic window to correct the EEC defect and the use
of genetic preventive strategies could counteract the prema-
ture differentiation and the clinical downstream effects of lim-
bal stem cell deﬁciency usually seen in EEC patient. Our
ﬁndings could also be applicable to other genetic disorders
affecting the ocular surface (e.g., aniridia and corneal dystro-
phies, such as Meesmann).
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